|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
42,345,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Vera Therapeutics is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Co.'s primary product candidate, atacicept, a self-administered fusion protein that blocks both blisibimod and APRIL, is being evaluated for the treatment of immunoglobulin A nephropathy in a global, randomized, double-blind, placebo-controlled clinical trial. Co. has obtained worldwide, exclusive development and commercial rights from Amplyx Pharmaceuticals, Inc., a wholly owned subsidiary of Pfizer Inc., for MAU868, a potentially monoclonal antibody to treat BK viremia infections.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
161,290 |
614,507 |
4,957,633 |
Total Buy Value |
$0 |
$4,999,990 |
$11,881,994 |
$42,392,668 |
Total People Bought |
0 |
1 |
3 |
8 |
Total Buy Transactions |
0 |
1 |
3 |
27 |
Total Shares Sold |
989,487 |
2,039,487 |
2,047,677 |
2,318,381 |
Total Sell Value |
$40,322,300 |
$59,222,300 |
$59,358,712 |
$64,660,810 |
Total People Sold |
3 |
4 |
7 |
8 |
Total Sell Transactions |
8 |
9 |
12 |
42 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
|
2024-05-16 |
4 |
S |
$42.22 |
$873,890 |
D/D |
(20,651) |
51,206 |
|
- |
|
Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
|
2024-05-16 |
4 |
OE |
$7.87 |
$162,523 |
D/D |
20,651 |
53,706 |
|
- |
|
Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
|
2024-05-15 |
4 |
S |
$42.17 |
$430,546 |
D/D |
(10,186) |
51,206 |
|
- |
|
Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
|
2024-05-15 |
4 |
OE |
$3.94 |
$32,387 |
D/D |
8,221 |
61,392 |
|
- |
|
Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
|
2024-04-10 |
4 |
S |
$40.00 |
$228,560 |
D/D |
(5,714) |
53,171 |
|
- |
|
Grant Sean |
CHIEF FINANCIAL OFFICER |
|
2024-04-03 |
4 |
S |
$38.20 |
$735,205 |
I/I |
(18,649) |
5,000 |
|
- |
|
Grant Sean |
CHIEF FINANCIAL OFFICER |
|
2024-04-03 |
4 |
S |
$38.13 |
$3,954,516 |
D/D |
(99,828) |
66,337 |
|
- |
|
Grant Sean |
CHIEF FINANCIAL OFFICER |
|
2024-04-03 |
4 |
OE |
$14.87 |
$1,484,442 |
D/D |
99,828 |
166,165 |
|
- |
|
Katabi Maha |
Director |
|
2024-03-25 |
4 |
S |
$40.50 |
$13,770,000 |
I/I |
(340,000) |
2,793,987 |
|
- |
|
Katabi Maha |
Director |
|
2024-03-22 |
4 |
S |
$40.51 |
$16,748,860 |
I/I |
(413,450) |
3,133,987 |
|
- |
|
Katabi Maha |
Director |
|
2024-03-21 |
4 |
S |
$43.00 |
$3,580,723 |
I/I |
(81,009) |
3,547,437 |
|
- |
|
Katabi Maha |
Director |
|
2024-01-30 |
4 |
B |
$31.00 |
$4,999,990 |
I/I |
161,290 |
3,628,446 |
2.1 |
- |
|
Grant Sean |
CHIEF FINANCIAL OFFICER |
|
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
78,683 |
|
- |
|
Young Joseph R |
SVP, FINANCE, CHIEF ACCT OFFCR |
|
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
21,875 |
57,054 |
|
- |
|
Fordyce Marshall |
PRESIDENT AND CEO |
|
2024-01-16 |
4 |
A |
$0.00 |
$0 |
D/D |
78,750 |
335,627 |
|
- |
|
Commodore Capital Lp |
10% Owner |
|
2024-01-10 |
4 |
S |
$18.00 |
$18,900,000 |
I/I |
(1,050,000) |
4,400,000 |
|
- |
|
Fordyce Marshall |
President and CEO |
|
2023-12-29 |
4 |
OE |
$2.32 |
$38,854 |
D/D |
13,516 |
256,877 |
|
- |
|
Grant Sean |
CHIEF FINANCIAL OFFICER |
|
2023-12-20 |
4 |
GD |
$0.00 |
$0 |
I/I |
636 |
18,021 |
|
- |
|
Fordyce Marshall |
President and CEO |
|
2023-08-21 |
4 |
AS |
$16.66 |
$86,779 |
D/D |
(5,210) |
243,361 |
|
- |
|
Lin Celia |
Chief Medical Officer |
|
2023-08-21 |
4 |
AS |
$16.65 |
$24,816 |
D/D |
(1,490) |
11,010 |
|
- |
|
Curley Joanne |
Chief Development Officer |
|
2023-08-21 |
4 |
AS |
$16.66 |
$24,817 |
D/D |
(1,490) |
26,962 |
|
- |
|
Grant Sean |
CHIEF FINANCIAL OFFICER |
|
2023-07-24 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,620 |
1,620 |
|
- |
|
Grant Sean |
CHIEF FINANCIAL OFFICER |
|
2023-07-24 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,620 |
18,657 |
|
- |
|
Young Joseph R |
SVP, Finance, Chief Acct Offcr |
|
2023-07-05 |
4 |
OE |
$3.94 |
$39,396 |
D/D |
10,000 |
32,679 |
|
- |
|
Grant Sean |
Chief Financial Officer |
|
2023-06-23 |
4 |
B |
$16.60 |
$83,000 |
I/I |
5,000 |
5,992 |
1.99 |
- |
|
138 Records found
|
|
Page 1 of 6 |
|
|